Neumora Therapeutics
Neumora is dedicated to revolutionizing neuroscience drug development to address the global brain disease crisis. They focus on developing targeted, effective medicines for brain diseases by leveraging scientific advancements and a precision medicine approach. Their pipeline includes programs targeting novel mechanisms of action in CNS diseases, supported by their Precision Toolbox, aiming to improve treatment options for the 1.5 billion people affected by brain disorders.
Industries
Nr. of Employees
medium (51-250)
Patents
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
US-12247037-B2
View DetailsCrystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
US-12171758-B1
View Details
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
US-12247037-B2
View DetailsCrystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
US-12171758-B1
View DetailsProducts
Selective kappa opioid receptor antagonist (late-stage clinical candidate)
Oral small-molecule KOR antagonist in late-stage clinical development for major depressive disorder; designed to modulate dopamine and reward-processing pathways.
V1a receptor antagonist (early clinical candidate)
Small-molecule V1a receptor antagonist in early clinical development for agitation in Alzheimer's disease.
M4 receptor modulator (preclinical candidate)
Small-molecule modulator targeting M4 receptor for schizophrenia indications in preclinical development.
NMDA receptor modulator (preclinical candidate)
Preclinical small-molecule modulator of NMDA receptor signaling for schizophrenia.
CK1δ inhibitor (preclinical candidate for neurodegeneration)
Small-molecule CK1δ inhibitor in preclinical development for ALS and Alzheimer's disease indications.
NLRP3 inhibitor (preclinical candidate for Parkinson's)
Preclinical small-molecule inhibitor of NLRP3 inflammasome pathway for Parkinson's disease.
Selective kappa opioid receptor antagonist (late-stage clinical candidate)
Oral small-molecule KOR antagonist in late-stage clinical development for major depressive disorder; designed to modulate dopamine and reward-processing pathways.
V1a receptor antagonist (early clinical candidate)
Small-molecule V1a receptor antagonist in early clinical development for agitation in Alzheimer's disease.
M4 receptor modulator (preclinical candidate)
Small-molecule modulator targeting M4 receptor for schizophrenia indications in preclinical development.
NMDA receptor modulator (preclinical candidate)
Preclinical small-molecule modulator of NMDA receptor signaling for schizophrenia.
CK1δ inhibitor (preclinical candidate for neurodegeneration)
Small-molecule CK1δ inhibitor in preclinical development for ALS and Alzheimer's disease indications.
NLRP3 inhibitor (preclinical candidate for Parkinson's)
Preclinical small-molecule inhibitor of NLRP3 inflammasome pathway for Parkinson's disease.
Services
End-to-end execution of clinical trials for CNS therapeutics, including trial design, enrollment, and data generation for regulatory submissions.
Development of translational studies and biomarker strategies to support patient stratification and mechanistic understanding in CNS programs.
Identification and execution of partnerships and in-licensing to expand therapeutic pipeline.
End-to-end execution of clinical trials for CNS therapeutics, including trial design, enrollment, and data generation for regulatory submissions.
Development of translational studies and biomarker strategies to support patient stratification and mechanistic understanding in CNS programs.
Identification and execution of partnerships and in-licensing to expand therapeutic pipeline.
Expertise Areas
- CNS drug discovery
- Translational neuroscience
- Clinical trial management (Phase 1–3)
- Clinical pharmacology and PK/PD
Key Technologies
- Computational translational analytics
- Translational biomarker development
- PET neuroimaging
- Electrophysiology (brain-slice and in vivo)